Sonoma Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Sonoma Pharmaceuticals, Inc. on August 27, 2025. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
Out of 1,642,765 shares entitled to vote, 718,469 shares were present or represented by proxy. The following proposals were voted upon:
- Proposal 1 (Election of Class II Director): Dr. Jay Birnbaum was elected. Votes cast: 123,034 For, 19,478 Withheld.
- Proposal 2 (Advisory Vote on Executive Compensation): Approved for the fiscal year ended March 31, 2025. Votes cast: 112,548 For, 26,360 Against, 3,604 Abstain.
- Proposal 3 (Ratification of Auditors): Frazier & Deeter, LLC was ratified for the fiscal year ending March 31, 2026. Votes cast: 702,484 For, 13,569 Against, 2,416 Abstain.
- Proposal 4 (Adjournment to Solicit Proxies): Approved to authorize adjournment if necessary. Votes cast: 576,908 For, 140,513 Against, 1,048 Abstain.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting (approximately 43.7%).
- Confirm the tenure and background of the newly elected Class II Director, Dr. Jay Birnbaum.
- Review the definitive proxy statement filed on July 11, 2025, for details on executive compensation and auditor fees.
- Note that the company's fiscal year ends on March 31, meaning the next financial reporting cycle will cover the period ending March 31, 2026.